OncoCyte
About: OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Employees: 46
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.41% less ownership
Funds ownership: 54.01% [Q2] → 53.6% (-0.41%) [Q3]
4% less capital invested
Capital invested by funds: $21.3M [Q2] → $20.4M (-$879K) [Q3]
17% less funds holding
Funds holding: 23 [Q2] → 19 (-4) [Q3]
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Needham Mike Matson 74% 1-year accuracy 84 / 114 met price target | 63%upside $4.25 | Buy Reiterated | 13 Nov 2024 |
Needham Mike Matson 74% 1-year accuracy 84 / 114 met price target | 63%upside $4.25 | Buy Reiterated | 15 Oct 2024 |
Financial journalist opinion
Based on 4 articles about OCX published over the past 30 days
